Collin C, Godbold J, Hajdu S, Brennan M
J Clin Oncol. 1987 Apr;5(4):601-12. doi: 10.1200/JCO.1987.5.4.601.
The management of extremity soft tissue sarcoma is undergoing rapid change as new techniques of adjuvant treatment are developed. Critical assessment of these advances requires a fundamental understanding of the natural course of this disease. In an effort to define important prognostic factors, this review of 423 adults with localized extremity soft tissue sarcomas, treated at one institution (1968 to 1978), was undertaken. The effect of the following variables on survival was examined: patient factors, ie, age, sex, symptoms, and status at presentation; tumor factors, ie, site, size, depth, bone or neurovascular invasion, histogenesis, grade, and nodal status; and treatment factors, ie, biopsy technique, type of operation, surgical margins, adjuvant treatment, and subsequent local treatment failure. Patient factors with an adverse impact on survival included age greater than 53 and the presence of local symptoms. High tumor grade, positive regional nodes, histology other than liposarcoma, fibrosarcoma or malignant fibrohistiocytoma, invasion of vital structures, proximal site, deep location, and size greater than 10 cm were also poor prognosticators. Treatment factors correlating with optimal survival included limb sparing surgery, adequate margins, biopsy with delayed definitive resection, and absence of subsequent local failure. Patients treated by amputation had a greater proportion of risk factors than patients treated with limb-sparing surgery (LSS). When the data were subjected to multivariate analysis, the following variables emerged as independent predictors of poor outcome: local symptoms, age greater than 53, high grade, proximal site, size greater than 10 cm, positive regional nodes, surgery by amputation, and inadequate margins. These factors are now to be evaluated in our prospective study based on 600 patients with soft tissue sarcoma of all sites admitted to our institution in the last 3 years. These factors should be considered as important stratifications in prospective trials.
随着辅助治疗新技术的发展,肢体软组织肉瘤的治疗正在迅速变革。对这些进展进行批判性评估需要对该疾病的自然病程有基本的了解。为了确定重要的预后因素,我们对在一家机构(1968年至1978年)接受治疗的423例局限性肢体软组织肉瘤成年患者进行了回顾性研究。研究了以下变量对生存的影响:患者因素,即年龄、性别、症状和就诊时的状态;肿瘤因素,即部位、大小、深度、骨或神经血管侵犯、组织发生、分级和淋巴结状态;以及治疗因素,即活检技术、手术类型、手术切缘、辅助治疗和随后的局部治疗失败。对生存有不利影响的患者因素包括年龄大于53岁和存在局部症状。肿瘤分级高、区域淋巴结阳性、组织学类型不是脂肪肉瘤、纤维肉瘤或恶性纤维组织细胞瘤、重要结构侵犯、近端部位、深部位置以及大小大于10 cm也是不良预后因素。与最佳生存相关的治疗因素包括保肢手术、足够的切缘、延迟确定性切除的活检以及无随后的局部失败。接受截肢治疗的患者比接受保肢手术(LSS)治疗的患者有更大比例的危险因素。当对数据进行多变量分析时,以下变量成为预后不良的独立预测因素:局部症状、年龄大于53岁、高级别、近端部位、大小大于10 cm、区域淋巴结阳性、截肢手术和切缘不足。这些因素现在将在我们基于过去3年入住我们机构的600例所有部位软组织肉瘤患者的前瞻性研究中进行评估。这些因素应被视为前瞻性试验中的重要分层因素。